Kinase inhibitors are now among the most important drugs in targeted therapy and are used in particular for the treatment of different tumor entities. Since many kinase inhibitors inhibit various tyrosine kinases efficiently but not specifically, they are often characterized by their versatile use in awide variety of entities and diseases. The diverse use of this group of drugs, as well as the challenge of their side-effect profile, continues to make kinase inhibitors the subject of numerous clinical studies. The following article provides an overview of recent new approvals in the field of kinase inhibitors and shows their importance for oncological therapy.
机构:
AP HP, Grp Hosp Cochin, Serv Med Interne 1, Med Oncol Unit, F-75679 Paris 14, FranceAP HP, Grp Hosp Cochin, Serv Med Interne 1, Med Oncol Unit, F-75679 Paris 14, France
Durand, JP
Goldwasser, E
论文数: 0引用数: 0
h-index: 0
机构:
AP HP, Grp Hosp Cochin, Serv Med Interne 1, Med Oncol Unit, F-75679 Paris 14, FranceAP HP, Grp Hosp Cochin, Serv Med Interne 1, Med Oncol Unit, F-75679 Paris 14, France
机构:
Univ Essen Gesamthsch, W German Canc Ctr, Dept Internal Med & Med Oncol, Essen, GermanyUniv Essen Gesamthsch, W German Canc Ctr, Dept Internal Med & Med Oncol, Essen, Germany
Strumberg, D
Seeber, S
论文数: 0引用数: 0
h-index: 0
机构:
Univ Essen Gesamthsch, W German Canc Ctr, Dept Internal Med & Med Oncol, Essen, GermanyUniv Essen Gesamthsch, W German Canc Ctr, Dept Internal Med & Med Oncol, Essen, Germany